Skip to main content

Philip Smalley

Philip Smalley has joined Wamberg Genomic Advisors as its chief medical director. An internal medicine specialist, Smalley will be responsible for WGA's medical research. Prior to joining the firm, he served as senior vice president and global chief medical officer for RGA International. He also served as managing director of the Longer Life Foundation, an RGA/Washington University in St. Louis partnership that funds research on the determinants of longevity and promoting quality and quantity of life. Smalley received his medical degree from the University of Toronto, after which he practiced and taught medicine at a University of Toronto-affiliated teaching hospital. He is a fellow of the Royal College of Physicians and Surgeons of Canada and past president of the Canadian Life Insurance Medical Officers Association.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.